<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Splenic marginal zone <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SMZL</z:e>) is a low-grade <z:hpo ids='HP_0002665'>lymphoma</z:hpo> showing a rather nonspecific immunophenotype </plain></SENT>
<SENT sid="1" pm="."><plain>Gene expression profiling studies suggested that TCL1A could be a marker of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SMZL</z:e>, but reported data are conflicting </plain></SENT>
<SENT sid="2" pm="."><plain>We evaluated TCL1A expression in a series of spleen and bone marrow samples involved by <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SMZL</z:e> and correlated the findings with other immunophenotypical, morphological, and clinical data </plain></SENT>
<SENT sid="3" pm="."><plain>In addition, we evaluated the expression of TCL1A in a series of spleens and lymph nodes involved by <z:hpo ids='HP_0002665'>lymphomas</z:hpo> that might mimic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SMZL</z:e> (13 nodal marginal zone <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (NMZL), 39 follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (FL), 30 B-cell <z:hpo ids='HP_0005550'>chronic lymphocytic leukemias</z:hpo> (B-CLL), 31 mantle cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e>), 1 lymphoplasmacytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo>) and 15 bone marrow specimens involving hairy cell <z:hpo ids='HP_0001909'>leukemia</z:hpo> (HCL) </plain></SENT>
<SENT sid="4" pm="."><plain>TCL1A staining was negative in 24/31 cases of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SMZL</z:e> (77 %); 27/31 MCL and <z:hpo ids='HP_0000001'>all</z:hpo> B-CLL were positive for TCL1A; 32/34 cases of nodal FL (96 %) and <z:hpo ids='HP_0000001'>all</z:hpo> five splenic FL were positive for TCL1A, although at a lower intensity </plain></SENT>
<SENT sid="5" pm="."><plain>Eight of 13 NMZL were positive for TCL1A, often showing a <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> staining pattern </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> HCL samples were strongly positive for TCL1A </plain></SENT>
<SENT sid="7" pm="."><plain>No correlation was found between the pattern of splenic infiltration, TCL1A expression, and the clinical course </plain></SENT>
<SENT sid="8" pm="."><plain>TCL1A-positive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SMZL</z:e> showed a higher rate of DBA44 staining compared to the negative ones, and this difference was statistically significant (Fisher test, single-tailed, p = 0.0397) </plain></SENT>
<SENT sid="9" pm="."><plain>Our data support the use of TCL1A in the panel of diagnostic markers used in the differential diagnosis of splenic low-grade B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>; a possible prognostic value, however, needs a larger series to be established </plain></SENT>
</text></document>